CODXNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Co-Diagnostics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.67+0.01 (+1.83%)
Close on Oct 19, 2026
- Market cap
- $2.87M
- P/E (TTM)
- –
- Dividend yield
- –
Co-Diagnostics, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product [Member] | $166.13K | $145.95K | – | – | $162.91K | $50.28K | – | – | – | – | – | – | 100.0% | +2.0% |
| Product Revenue [Member] | – | – | – | $145.38K | $162.91K | $50.28K | $149.33K | $206.88K | $161.10K | $252.75K | $55.18K | $136.53K | – | – |
| Grant Revenue [Member] | – | – | – | – | – | – | $0 | $434.27K | $2.50M | $215.11K | $3.50M | $2.32M | – | – |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $105.39K | $81.05K | $241.72K | $136.74K | $162.91K | $40.18K | – | $564.04K | $2.63M | $301.40K | $3.54M | $2.41M | 63.4% | -35.3% |
| Non-US [Member] | $60.75K | $64.90K | $22.20K | $8.64K | $0 | $10.10K | $244.60K | $77.10K | – | – | – | – | 36.6% | – |
| Rest of World [Member] | – | – | – | – | $0 | $10.10K | $244.60K | $77.10K | $23.69K | $166.45K | $14.05K | $48.43K | – | – |
From the segment and revenue-disaggregation notes of Co-Diagnostics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.